Date: 2013-07-30
Type of information: Development agreement
Compound: compounds inhibiting the protein kinase TTK/MPS1
Company: Nerviano Medical Sciences (Italy) Servier (France)
Therapeutic area: Cancer - Oncology
Type agreement: development
licensing
commercialisation
Action mechanism:
Disease:
Details: * On July 30, 2013, Nerviano Medical Sciences, an italian oncology-focused, integrated discovery and development companies in Europe, and Servier, a leading research-based European pharmaceutical company have announced a collaboration and worldwide license agreement to further develop and commercialize first-in-class Nerviano compounds inhibiting the protein kinase TTK/MPS1. A key regulator of mitosis TTK/MPS1 is aberrantly overexpressed in a wide range of tumours and represents a promising target in oncology.
Under the terms of the agreement, Nerviano will complete the preclinical development of the lead candidate drug and, if Servier exercises the option, Servier will bear all development and commercialization costs. Nerviano will continue to support Servier for the early clinical development and the supply of the licensed product.
“We have preclinical data which suggest that TTK may represent an attractive therapeutic target in a poor prognosis associated subgroup of breast cancer”, said Stéphane Depil, M.D., Ph.D., director of Oncology R&D at Servier.
Financial terms: Terms of the collaboration include an upfront fee of € 8 million and a potential for up to € 100 million in option fees, clinical and regulatory milestones in addition to royalties for the sale of licensed products.
Latest news:
